Meeting
2018 ASCO Annual Meeting
Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
Authors
Karyn A. Goodman
University of Colorado, Denver, CO
Karyn A. Goodman , Nathan Hall , Tanios S. Bekaii-Saab , Fang-Shu Ou , Erin Twohy , Michael O. Meyers , Daniel J. Boffa , Kisha Mitchell , Kyle Perry , Wendy L Frankel , Alan P. Venook , Eileen Mary O'Reilly , David H. Ilson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT01333033
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4012)
DOI
10.1200/JCO.2018.36.15_suppl.4012
Abstract #
4012
Poster Bd #
201
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Preoperative chemoradiation (CRT) with carboplatin (CBP)/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: A randomized phase 2 trial.
First Author: Antoine Adenis
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study.
First Author: Richard Francis Dunne
Poster
2018 ASCO Annual Meeting
Induction chemoradiotherapy for esophageal cancer: Comparing CROSS regimen with cisplatin/5-FU.
First Author: Abraham Geller
Poster
2017 ASCO Annual Meeting
Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer.
First Author: Hao-Wen Sim